Dexamethasone
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Dexamethasone: Alopecia mucinosa
One-Sentence Summary
Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive activity. The TxGNN model predicts it may be useful for alopecia mucinosa, but no clinical trials and no publications were found to support this prediction. It rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for dexamethasone are not available in the data compiled for this report. As a glucocorticoid, it is generally understood to suppress inflammatory signalling and reduce immune-cell infiltration.
Alopecia mucinosa (follicular mucinosis) is characterised by mucin deposits around hair follicles together with an inflammatory cell infiltrate. A corticosteroid’s anti-inflammatory action could plausibly act on this infiltrate, which is the reasoning behind the model’s high score.
This is a theoretical rationale only. No trial, case series or other publication on dexamethasone in this condition was provided. Route suitability is also unassessed: the locally recorded dexamethasone products are injectable, oral and eye-drop forms, and no skin-directed form is recorded.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Dexamethasone is marketed in India as a single-ingredient product. All licences in the local records are valid and none are cancelled. The licences listed below are a selection of the main ones, and the record may be partial.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 241707 | Wymesone 4mg Injection (Pfizer Ltd) | Vial of 2 ml injection | Not specified |
| 65348 | Decamycin 4mg Injection (Sun Pharmaceutical Industries Ltd) | Vial of 20 ml injection | Not specified |
| 68468 | Dexford 8mg Tablet (Garwyn Remedies) | Strip of 10 tablets | Not specified |
| 58248 | Dexona Tablet (Zydus Cadila) | Strip of 30 tablets | Not specified |
| 66222 | Dexacort Eye Drop (Kaizen Pharmaceuticals Pvt Ltd) | Packet of 5 ml eye drop | Not specified |
Safety Considerations
- Drug Interactions: The interaction database lists 913 interacting drugs for dexamethasone. Examples:
- Major: fentanyl, adalimumab
- Moderate: paclitaxel, abemaciclib, zidovudine, nifedipine, ibuprofen, ketorolac, acetazolamide, isotretinoin
- Minor: dolutegravir, lidocaine, formoterol
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. No clinical trials or publications address dexamethasone in alopecia mucinosa, so the evidence level is L5. The anti-inflammatory rationale is plausible but unverified.
To proceed, the following is needed:
- A systematic literature search for corticosteroid use in alopecia mucinosa, including case reports and case series
- Mechanism-of-action data for dexamethasone to support the mechanistic link
- Assessment of which route of administration would suit this condition, compared with the locally available injectable, oral and eye-drop forms
- Package insert warnings and contraindications from the local licence holders, to support a safety review
- A review of the drug interaction profile (including the major interactions above) for the likely patient population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.